Detalles de la búsqueda
1.
Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial.
Cancer
; 2024 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38630903
2.
Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women's Health Initiative.
Cancer
; 2024 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38736319
3.
Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis.
Oncologist
; 2024 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38656345
4.
Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis.
Breast Cancer Res Treat
; 2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38653905
5.
Ductal carcinoma in situ and cause-specific mortality among younger and older postmenopausal women: the Women's Health Initiative.
Breast Cancer Res Treat
; 2024 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38730133
6.
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer.
Gynecol Oncol
; 182: 124-131, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38262235
7.
Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
Cancer
; 129(5): 740-749, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36517940
8.
Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates.
Oncologist
; 28(9): e843-e846, 2023 09 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37335880
9.
Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer.
Oncologist
; 28(7): e488-e492, 2023 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36943382
10.
Predicting All-Cause Mortality in Women With and Without Breast Cancer Using the Schonberg Index: A Women's Health Initiative Study.
J Natl Compr Canc Netw
; 21(6): 636-644.e13, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37308127
11.
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
J Natl Compr Canc Netw
; 21(6): 594-608, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37308117
12.
The relationship between sleep and weight change among women diagnosed with breast cancer participating in the Women's Health Initiative.
Breast Cancer Res Treat
; 192(2): 423-433, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35006483
13.
A Cross-Sectional Study of Distress Levels in Patients with Newly Diagnosed Breast Cancer: The Impact of Race, Ethnicity, and Language Preference.
Ann Surg Oncol
; 29(2): 981-988, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34585296
14.
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(6): 691-722, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35714673
15.
Cardiometabolic risk factors, physical activity, and postmenopausal breast cancer mortality: results from the Women's Health Initiative.
BMC Womens Health
; 22(1): 32, 2022 02 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35120497
16.
Metabolic syndrome risk components and mortality after triple-negative breast cancer diagnosis in postmenopausal women in the Women's Health Initiative.
Cancer
; 127(10): 1658-1667, 2021 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33476042
17.
Low-fat dietary pattern and breast cancer mortality by metabolic syndrome components: a secondary analysis of the Women's Health Initiative (WHI) randomised trial.
Br J Cancer
; 125(3): 372-379, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34006923
18.
Recall of Genomic Testing Results Among Patients with Cancer.
Oncologist
; 26(12): e2302-e2305, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34355454
19.
A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.
Oncologist
; 26(2): 99-e217, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33141975
20.
Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Oncologist
; 26(3): e382-e393, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33098195